CHICAGO, IL—Patients with locally advanced nasopharyngeal cancer (NPC) do not benefit from the addition of neoadjuvant gemcitabine, carboplatin, and paclitaxel (GCP) to cisplatin chemoradiation.
CHICAGO, IL—Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients’ quality of life.
Patients who receive radiotherapy for head and neck cancer may now have an effective way to combat pain from oral mucositis.
ANAHEIM, CALIFORNIA—Among oropharyngeal patients receiving radiotherapy, gabapentin improved pain management and reduced weight loss, which potentially prevents the need for placement of a gastrostomy tube.
Oral HPV, HPV16 DNA commonly detected in patients with oropharyngeal cancer, but not their partners.
Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus, specifically HPV 16 or 18.
Patients with HPV-positive OPSCC report different symptoms than those with HPV-negative OPSCC, which may have an effect on how early the disease is diagnosed.
No differences in cancer incidence with VPA use for cancers of the lung, bladder, colon or prostate.
Barbara Burtness, MD, comments on the rising incidence of thyroid cancer, which potentially results from overdiagnosis.
The FDA has accepted the Supplemental New Drug Application and granted it Priority Review for the expanded use of Lymphoseek Injection for sentinel lymph node detection in patients with head and neck cancer.
